Literature DB >> 16615001

Indomethacin enhances bile salt detergent activity: relevance for NSAIDs-induced gastrointestinal mucosal injury.

M Petruzzelli1, A Moschetta, W Renooij, M B M de Smet, G Palasciano, P Portincasa, K J van Erpecum.   

Abstract

Gastroduodenal toxicity of nonsteroidal anti-inflammatory drugs (NSAIDs) is partly independent from cyclooxygenase inhibition, possibly related to increased intermixed micellar-vesicular (nonphospholipid-associated) bile salt concentrations thought to be responsible for bile salt cytotoxicity. We evaluated the effects of indomethacin on bile salt cytotoxicity with complementary in vitro and ex vivo systems. In the erythrocyte model, indomethacin alone did not induce hemolysis. In contrast, indomethacin enhanced and phospholipids decreased hemolysis induced by hydrophobic taurodeoxycholate (TDC). Hydrophilic tauroursodeoxycholate (TUDC) enhanced rather than decreased TDC-induced hemolysis in the presence of indomethacin. Indomethacin did not affect intermixed micellar-vesicular bile salt concentrations or compositions. Indomethacin also increased TDC-induced lactate dehydrogenase release in CaCo-2 cells and bile salt-induced rat colonic mucosal injury, and prevented potential protective effects of TUDC in these systems. Our data show that indomethacin enhances bile salt-induced cytotoxicity without affecting intermixed micellar-vesicular bile salt concentrations or compositions. These findings may be relevant for gastroduodenal injury during NSAID therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16615001     DOI: 10.1007/s10620-006-3204-1

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  38 in total

1.  Accurate separation of vesicles, micelles and cholesterol crystals in supersaturated model biles by ultracentrifugation, ultrafiltration and dialysis.

Authors:  A Moschetta; E R Eckhardt; M B De Smet; W Renooij; G P Van Berge-Henegouwen; K J Van Erpecum
Journal:  Biochim Biophys Acta       Date:  2001-05-31

2.  Sphingomyelin exhibits greatly enhanced protection compared with egg yolk phosphatidylcholine against detergent bile salts.

Authors:  A Moschetta; G P vanBerge-Henegouwen; P Portincasa; G Palasciano; A K Groen; K J van Erpecum
Journal:  J Lipid Res       Date:  2000-06       Impact factor: 5.922

3.  Prevention of aspirin-induced gastric ulceration by bile duct or pylorus ligation in the rat.

Authors:  B Djahanguiri; F S Abtahi; M Hemmati
Journal:  Gastroenterology       Date:  1973-10       Impact factor: 22.682

4.  Two dimensional then layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots.

Authors:  G Rouser; S Fkeischer; A Yamamoto
Journal:  Lipids       Date:  1970-05       Impact factor: 1.880

5.  Cell type-dependent effect of phospholipid and cholesterol on bile salt cytotoxicity.

Authors:  A L Velardi; A K Groen; R P Elferink; R van der Meer; G Palasciano; G N Tytgat
Journal:  Gastroenterology       Date:  1991-08       Impact factor: 22.682

6.  Hydrophilic bile salts enhance differential distribution of sphingomyelin and phosphatidylcholine between micellar and vesicular phases: potential implications for their effects in vivo.

Authors:  A Moschetta; G P vanBerge-Henegouwen; P Portincasa; W L Renooij; A K Groen; K J van Erpecum
Journal:  J Hepatol       Date:  2001-04       Impact factor: 25.083

7.  Conjugates of ursodeoxycholate protect against cytotoxicity of more hydrophobic bile salts: in vitro studies in rat hepatocytes and human erythrocytes.

Authors:  D M Heuman; W M Pandak; P B Hylemon; Z R Vlahcevic
Journal:  Hepatology       Date:  1991-11       Impact factor: 17.425

8.  Importance of local versus systemic effects of non-steroidal anti-inflammatory drugs in increasing small intestinal permeability in man.

Authors:  I Bjarnason; B Fehilly; P Smethurst; I S Menzies; A J Levi
Journal:  Gut       Date:  1991-03       Impact factor: 23.059

9.  Quantitative estimation of the hydrophilic-hydrophobic balance of mixed bile salt solutions.

Authors:  D M Heuman
Journal:  J Lipid Res       Date:  1989-05       Impact factor: 5.922

10.  Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis.

Authors:  S E Gabriel; L Jaakkimainen; C Bombardier
Journal:  Ann Intern Med       Date:  1991-11-15       Impact factor: 25.391

View more
  5 in total

1.  Effect of indomethacin on bile acid-phospholipid interactions: implication for small intestinal injury induced by nonsteroidal anti-inflammatory drugs.

Authors:  Yong Zhou; Elizabeth J Dial; Rand Doyen; Lenard M Lichtenberger
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-03-04       Impact factor: 4.052

2.  In vitro evidence that phosphatidylcholine protects against indomethacin/bile acid-induced injury to cells.

Authors:  Elizabeth J Dial; Paul A Dawson; Lenard M Lichtenberger
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-12-04       Impact factor: 4.052

3.  Aggregation behavior of ibuprofen, cholic acid and dodecylphosphocholine micelles.

Authors:  Priyanka Prakash; Abdallah Sayyed-Ahmad; Yong Zhou; David E Volk; David G Gorenstein; Elizabeth Dial; Lenard M Lichtenberger; Alemayehu A Gorfe
Journal:  Biochim Biophys Acta       Date:  2012-08-04

4.  Cattle bile aggravates diclofenac sodium-induced small intestinal injury in mice.

Authors:  Hironori Ishikawa; Shiro Watanabe
Journal:  Evid Based Complement Alternat Med       Date:  2011-04-11       Impact factor: 2.629

5.  The Nonsteroidal Anti-Inflammatory Drug Ketorolac Alters the Small Intestinal Microbiota and Bile Acids Without Inducing Intestinal Damage or Delaying Peristalsis in the Rat.

Authors:  Barbara Hutka; Bernadette Lázár; András S Tóth; Bence Ágg; Szilvia B László; Nóra Makra; Balázs Ligeti; Bálint Scheich; Kornél Király; Mahmoud Al-Khrasani; Dóra Szabó; Péter Ferdinandy; Klára Gyires; Zoltán S Zádori
Journal:  Front Pharmacol       Date:  2021-06-04       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.